Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcus Biosciences Inc RCUS

Healthcare Biotechnology
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical... see more

Recent & Breaking News (NYSE:RCUS)

Arcus Biosciences to Present at Upcoming Investor Conferences

Business Wire July 29, 2019

Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer

Business Wire June 24, 2019

Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs

Business Wire June 11, 2019

Arcus Biosciences to Present Preliminary Data from the Ongoing Phase 1 Dose-Escalation Trials of AB928 in Combination with Chemotherapy or AB122 at the 2019 ASCO Annual Meeting

Business Wire May 29, 2019

Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

Business Wire May 21, 2019

Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates

Business Wire May 2, 2019

Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer

Business Wire May 2, 2019

Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122

Business Wire May 2, 2019

Arcus Biosciences Appoints Rekha Hemrajani as Chief Operating and Financial Officer

Business Wire March 25, 2019

Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates

Business Wire March 5, 2019

Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting

Business Wire February 28, 2019

Arcus Biosciences Announces Participation at Upcoming Investor Conference

Business Wire February 13, 2019

Arcus Biosciences Announces Transition of Chief Financial and Operating Officer

Business Wire January 4, 2019

Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 16, 2018

Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting

Business Wire November 9, 2018

Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates

Business Wire November 8, 2018

Arcus Biosciences Announces Participation at Three Investor Conferences in November

Business Wire November 1, 2018

Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors

Business Wire October 22, 2018

Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress

Business Wire October 8, 2018

Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting

Business Wire October 2, 2018